Completed

Aliskiren vs Losartan for Hypertension with Hyperuricemia

What is being tested

Aliskiren

+ Losartan

Drug

Who is being recruted

Essential Hypertension+4

+ Cardiovascular Diseases

+ Hypertension

From 37 to 81 Years

+15 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledPhase 4

Interventional

Study Start: May 2021

See protocol details

Summary

Principal SponsorHansung University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2021

Actual date on which the first participant was enrolled.

This clinical trial explores whether Aliskiren is just as effective as Losartan in treating high blood pressure in people who also have high uric acid levels, a condition known as hyperuricemia. Hypertension and hyperuricemia often occur together and can worsen each other, increasing the risk of heart and kidney problems. Both Aliskiren and Losartan are commonly used for high blood pressure, but their impact on uric acid levels and kidney health hasn't been fully understood. This study aims to fill that gap, potentially improving treatment options for patients with these conditions. In this study, 66 participants will be randomly divided into two groups to receive either Aliskiren, taken as a 240 mg pill daily, or Losartan, taken as a 100 mg pill daily, over a period of three months. The main focus will be on changes in uric acid levels in the blood before and after the treatment. Secondary measurements will include changes in blood pressure, kidney function as indicated by creatinine levels and estimated glomerular filtration rate (eGFR), and any side effects experienced. This will help determine if Aliskiren is not only effective in managing blood pressure but also if it has a more favorable effect on kidney health compared to Losartan.

Official TitleNon-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia

NCT06718062

Principal SponsorHansung University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

66 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 37 to 81 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Essential HypertensionCardiovascular DiseasesHypertensionPathologic ProcessesPathological Conditions, Signs and SymptomsVascular DiseasesHyperuricemia

Criteria

7 inclusion criteria required to participate

Diagnosed with Hypertension

Diagnosed with Hyperuricemia

Serum uric acid levels between 420 μmol/L and 700 μmol/L

Age between 18 and 80 years

Show More Criteria

8 exclusion criteria prevent from participating

Diagnosis of Gout

History of secondary hypertension

Severe organ dysfunction, including liver, kidney, or heart failure

History of malignant tumors

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Placebo

Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the approval number National Drug Approval No. H20138002. The patients will take Aliskiren orally once a day for 3 months. The primary objective is to assess the non-inferiority of Aliskiren in lowering serum uric acid levels, as well as its effects on blood pressure and kidney function.

Group II

Active Comparator

Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the approval number National Drug Approval No. H20143030. The patients will take Losartan orally once a day for 3 months. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Chancheng District People's Hospital, Foshan City

Foshan, ChinaOpen Chancheng District People's Hospital, Foshan City in Google Maps

CompletedOne Study Center